Home | Reports | Startups | Press Releases | Blog | Online Store | site map


Developments

Financings

Reports

Startups
blog
Blog
Medtech podcast
Podcast

Cardiology

Surgery

Methodology

Order Report via our online store
or via order form

See the December 2010 Report #S835: Worldwide Obesity 2011-2019
Click HERE for more details.

 

This report has been superseded by report #S835
Products, Technologies and Markets Worldwide in the
Clinical Management of Obesity

Report S800

 

s 268 pages   s 81 Exhibits   s 34 Company Profiles   s Published October 2004   s Report #S800

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient worldwide population in obesity, detailing their incidence, the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches.  The report describes clinical trends in the management of the obese. The report will detail the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products worldwide.   The report profiles 34 companies in this market, detailing the current products, products in development, market position and overall businesses in obesity management.

Table of Contents

Executive Summary

 

Section 1:   Introduction

1.1   Overview

1.2   Definitions

1.3   Clinical Background

1.3.1   Prevalence in the US Population

1.3.2   Prevalence of Obesity Worldwide

1.3.2.1   Europe

1.3.2.2   Japan

1.3.2.3   China

1.3.2.4   Developed Nations vs. Developing Nations

1.4   Patient Population Segmentation

1.4.1   Adults

1.4.2   Adolescents

1.4.3   Children

1.5   Overweight, Obesity and Morbidity

1.5.1   The Multifactorial Causes of Obesity

1.5.1.1   The Appetite Regulatory System—Facts and Theories

1.5.1.1.1   Insulin

1.5.1.1.2   Leptin: The Ups and Downs of a Promising Lead

1.5.1.1.3   Ghrelin

1.5.1.1.4   Peptide YY (PYY) & the Y2 Receptor

1.5.1.1.5   AMPK

1.5.1.1.6   Role of the Hypothalamus

1.5.1.1.7   Melanocortins & Serotonin

1.5.1.2   The Body’s Fight to Retain Fat

1.5.1.3   Body Mass Index (BMI)

1.5.1.4   Genetic Roots of Obesity

1.5.1.4.1   Congenital Leptin Deficiency

1.5.1.4.2   Genetic Association Studies

1.5.1.4.3   Genetic Testing For Predisposition Towards Obesity

1.5.2   Obesity, Lifestyle and the ‘Obesogenic’ Environment

1.5.2.1   Feeding Control

1.5.2.2   Energy Efficiency

1.5.2.3   Adipose Tissue Biology

1.5.2.4   Abdominal Girth as a Warning Sign

1.5.3   Metabolic Syndrome, or Syndrome X

1.5.4   Obesity and Cancer

1.5.5   Binge Eating Disorder (BED)

1.5.6   Night Eating Syndrome (NES)

1.5.7   Why Treat Obesity?

Section 2:   Weight loss management approaches

2.1   Surgical Approaches

2.1.1   Background and Professional Certification Efforts

2.1.2   Gastric Bypass, Mini Gastric Bypass and Laparoscopic Surgery

2.1.2.1   Gastric Bypass, or Roux-en-Y Surgery

2.1.2.2   Mini Gastric Bypass

2.1.2.3   Laparoscopic Surgery

2.1.3   Biliopancreatic Diversion/Duodenal Switch (BPD/DS)

2.1.4   Two-Stage Weight Loss Surgery

2.1.5   Vertical Banded Gastroplasty (VBG) and Mini-SRVG

2.1.6   Adjustable Gastric Band (AGB) Surgery

2.1.7   Internal or Implantable Gastric Stimulation (IGS) Device

2.1.8   Gastric Balloon

2.1.9   Radio-frequency Antralplasty

2.2   Pharmaceutical Therapies

2.2.1   Pancreatic Lipase Inhibitors

2.2.1.1   The XENDOS Study

2.2.1.2   ATL-962

2.2.2   Serotonin and Norepinephrine Reuptake Inhibitors

2.2.2.1   Sibutramine

2.2.2.2   5-HT2C Agonists

2.2.3   Noradrenergic Anorectic Agents

2.2.4   Other Pharmaceutical Therapies Under Development

2.3   Non-pharmacological Approaches

2.3.1   Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)

2.3.2   Behavior Modification

2.3.3   Residential and Intensive Programs

2.3.3.1   The Aimin Fat Reduction Hospital, Tianjin, China

2.3.3.2   Carnegie International Weight Loss Camp, Leeds, United Kingdom

2.4   False Starts, Fads and Empty Promises

2.4.1   The FDA’s Withdrawal of ‘Fen-Phen’ From the US Market

2.4.2   Ephedra and the USFDA

2.5   Weight Maintenance Approaches

Section 3:   Impact of obesity

3.1   Obesity Treatments, Related Costs and Reimbursement

3.1.1   Impact Upon Insurance Costs

3.1.2   Cost of Treatment of Obesity, versus Long-term Cost to Treat Related Conditions

3.2   Impact Upon Business/Economy

3.2.1   US

3.2.2   United Kingdom

3.3   The Government Enters the Fray

3.3.1   USA

3.3.1.1   Medicare Debates Gastric Bypass Surgery

3.3.1.2   Insurance and Mandated Coverage Bills

3.3.1.3   IRS and Deduction of Obesity Treatments

3.3.1.4   FDA Changing Approval Process of Obesity Drugs

3.3.2   United Kingdom: NICE & Weight Management at the Primary Care Level

3.3.3   France: The Caisse Nationale d’Assurance Maladie (CNAM)

Section 4:   Clinical trends

4.1   Pharmaceuticals: Gastrointestinal versus CNS Targets

4.1.1   Anti-Absorption Therapeutics

4.1.2   Appetite and Satiety Therapeutics

4.1.3   Gastrointestinal versus Central Nervous System Targets

4.2   Surgical Treatment

4.3   Tailoring the Strategy to the Patient

4.4   Other Clinical Trends

Section 5:   Products & Technologies

5.1   Bariatric Surgery Devices

5.1.1   Bariatric Surgery Devices in Use and Under Development

5.2   Drug Development

5.2.1   Pharmaceutical Products Currently on the Market and Under Development

5.2.2   Sanofi-Aventis’s Rimonabant

5.2.3   The Hormone Oleoyl-Estrone for Morbid Obesity

5.2.4   Johnson & Johnson’s Topamax®

5.2.5   Biopharmaceuticals

5.2.5.1   5-HT2C Agonists

5.2.5.2   ATL-962

5.3   Gastric Stimulation Devices

5.3.1   Gastric Stimulation Devices Currently on the Market and Under Development

5.4   Brain Stimulation Devices

5.4.1   Brain Stimulation Devices Currently on the Market and Under Development

5.5   Radio-Frequency Antralplasty Device

5.5.1   Radio-Frequency Antralplasty Devices Currently on the Market and Under Development

5.6   Combination Therapies

5.6.1   Combination Therapies Currently on the Market and Under Development

5.6.2   Combination of Surgery and Drugs

5.6.3   Combinations of Drugs

5.7   Genetic Therapies

5.7.1   Genetic Therapies Currently on the Market and Under Development

Section 6:   Market Assessment

6.1   Bariatric Surgery Devices

6.1.1   United States and Canada

6.1.2   European Union

6.1.2.1   United Kingdom

6.1.2.2   France

6.1.2.3   Germany

6.1.2.4   Italy

6.1.2.5   Spain

6.1.2.6   Scandinavia

6.1.3   Japan

6.1.4   Rest of World (ROW)

6.2   Pharmaceuticals

6.2.1   United States and Canada

6.2.2   Pharmaceutical Treatments in the European Union

6.2.2.1   United Kingdom

6.2.2.2   France

6.2.2.3   Germany

6.2.2.4   Italy

6.2.2.5   Spain

6.2.2.6   Scandinavia

6.2.3   Japan

6.2.3.1   Healthcare reform

6.2.4   Rest of World (ROW)

6.2.5   Developing Drugs for Tomorrow, While Maximizing Profits Today

Section 7:   Opportunities

7.1   Focus on Pharmaceuticals

7.2   Focus on Medical Devices

7.3   Durable Medical Equipment for the Bariatric Patient

7.4   Strategic Mergers and Acquisitions

7.5   Focus on Education and Practice Consulting

7.6   A Key to Success: Working With Government Healthcare Systems, Insurance Programs and Medicare

Section 8:   Company Profiles

8.1   Abbott Laboratories

8.2   AdipoGenix

8.3   Alizyme plc

8.4   Amgen

8.5   Amylin Pharmaceuticals

8.6   AstraZeneca

8.7   Athersys, Inc.

8.8   Bayer AG

8.9   Biovitrum AB

8.10   CuraGen Corporation

8.11   DeCODE Genetics

8.12   DeveloGen AG

8.13   Ethicon Endo-Surgery/Johnson & Johnson

8.14   GenWay Biotech, Inc.

8.15   GlaxoSmithKline

8.16   Inamed Corporation

8.17   Ingenium Pharmaceuticals AG

8.18   IntraPace, Inc.

8.19   Johnson & Johnson

8.20   Manhattan Pharmaceuticals, Inc.

8.21   Merck & Co., Inc.

8.22   Metabolic Pharmaceuticals Ltd

8.23   Millennium Pharmaceuticals

8.24   Myriad Genetics

8.25   Nastech Pharmaceutical Company, Inc.

8.26   Pfizer, Inc.

8.27   Regeneron Pharmaceuticals

8.28   Roche (F Hoffman-La Roche Ltd)

8.29   Sanofi-Aventis

8.30   Speedel Group AG

8.31   Synovis Life Technologies Inc.

8.32   Transneuronix, Inc.

8.33   Vista Medical Technologies, Inc.

8.34   Wyeth Pharmaceuticals

Appendix: List of Companies

ABBREVIATIONS

 

Exhibit ES-1:  Worldwide Obesity Devices Market Forecast, 2002-2013 (US$M)

Exhibit 1-1:  Relationship Between BMI and Risk of Disease

Exhibit 1-2:  Elements Contributing to the Obesity Epidemic

Exhibit 1-3:  Prevalence of Obesity, Percent of Population (2003)

Exhibit 1-4:  WHO Graph of Obesity, 2004

Exhibit 1-5:  Worldwide Total, Obese and Morbidly Obese, 2002-2013

Exhibit 1-6:  Examples of Definitions Used and Age Groups Included in Surveys Reporting Prevalence of Obesity

Exhibit 1-7:  Examples of Human Pleiotropic Obesity Syndromes

Exhibit 1-8:  Leptin’s Role in the Body

Exhibit 1-9:  Candidate Genes for Control of Appetite, Energy Expenditure, Usage of Nutrients and Body Fat Distribution

Exhibit 2-1:  IFSO and Minimum Professional Requirements for the Practicing Bariatric Surgeon

Exhibit 2-2:  Gastric Bypass Surgery

Exhibit 3-1:  Examples of Annual National Costs of Obesity (US$ Millions)

Exhibit 3-2:  Examples of US Insurance Company Obesity Coverage Policies

Exhibit 5-1:  Bariatric Surgery Procedures in Use and Under Development

Exhibit 5-2:  Market Shares of Companies in Bariatric Surgery Devices

Exhibit 5-3:  Pharmaceutical Products Currently on the Market and Under Development

Exhibit 5-4:  Market Shares of Meridia and Xenical, 2004

Exhibit 5-5:  Gastric Stimulation Devices Currently on the Market and Under Development

Exhibit 5-6:  Brain Stimulation Devices Currently on the Market and Under Development

Exhibit 5-7:  Radio-Frequency Antralplasty Devices Currently on the Market and Under Development

Exhibit 5-8:  Combination Therapies Currently on the Market and Under Development

Exhibit 5-9:  Genetic Therapies Currently on the Market and Under Development

Exhibit 6-1:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)

Exhibit 6-2:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2002-2013 (US$M)

Exhibit 6-3:  Bariatric Surgery Devices, Total Market Forecast, 2002-2013

Exhibit 6-4:  Total Bariatric Surgery Devices Market Forecast, 2002-2013 (US$M)

Exhibit 6-5:  Bariatric Surgery Devices, Market Forecast, United States and Canada, 2002-2013

Exhibit 6-6:  Bariatric Surgery Devices, Market Forecast, US and Canada, 2002-2013

Exhibit 6-7:  US Obesity Treatment Medical Device Company Market Shares, 2013

Exhibit 6-8:  Bariatric Surgery Devices, Market Forecast, European Union, 2002-2013

Exhibit 6-9:  Bariatric Surgery Devices, Country Market Shares, European Union, 2004

Exhibit 6-10:  Bariatric Surgery Devices, Market Forecast, United Kingdom, 2002-2013

Exhibit 6-11:  Bariatric Surgery Devices, Market Forecast, United Kingdom 2002-2013

Exhibit 6-12:  Bariatric Surgery Devices, Market Forecast, France, 2002-2013

Exhibit 6-13:  Bariatric Surgery Devices, Market Forecast, France, 2002-2013

Exhibit 6-14:  Bariatric Surgery Device Market Shares, France, 2004

Exhibit 6-15:  Bariatric Surgery Devices, Market Forecast, Germany, 2002-2013

Exhibit 6-16:  Bariatric Surgery Devices, Market Forecast, Germany 2002-2013

Exhibit 6-17:  Bariatric Surgery Device Market Shares, Germany, 2004

Exhibit 6-18:  Bariatric Surgery Devices, Market Forecast, Italy, 2002-2013

Exhibit 6-19:  Bariatric Surgery Devices, Market Forecast, Italy 2002-2013

Exhibit 6-20:  Bariatric Surgery Devices, Market Forecast, Spain, 2002-2013

Exhibit 6-21:  Bariatric Surgery Devices, Market Forecast, Spain 2002-2013

Exhibit 6-22:  Bariatric Surgery Devices, Market Forecast, Scandinavia, 2002-2013

Exhibit 6-23:  Bariatric Surgery Devices, Market Forecast, Scandinavia 2002-2013

Exhibit 6-24:  Bariatric Surgery Devices, Market Forecast, Japan, 2002-2013

Exhibit 6-25:  Bariatric Surgery Devices, Market Forecast, Japan 2002-2013

Exhibit 6-26:  Bariatric Surgery Devices, Market Forecast, Rest of World, 2002-2013

Exhibit 6-27:  Bariatric Surgery Devices, Market Forecast, ROW 2002-2013

Exhibit 6-28:  Total Pharmaceutical Sales, Market Forecast, 2002-2013

Exhibit 6-29:  Obesity Drugs, Market Forecast, USA and Canada, 2002-2013

Exhibit 6-30:  Obesity Drugs, Market Forecast, USA and Canada, 2002-2013

Exhibit 6-31:  Obesity Drugs, Market Forecast, European Union, 2002-2013

Exhibit 6-32:  Obesity Drugs, Market Forecast, United Kingdom, 2002-2013

Exhibit 6-33:  Obesity Drugs, Market Forecast, United Kingdom, 2002-2013

Exhibit 6-34:  Obesity Drugs, Market Forecast, France, 2002-2013

Exhibit 6-35:  Obesity Drugs, Market Forecast, France, 2002-2013

Exhibit 6-36:  Obesity Drugs, Market Forecast, Germany, 2002-2013

Exhibit 6-37:  Obesity Drugs, Market Forecast, Germany, 2002-2013

Exhibit 6-38:  Obesity Drugs, Market Forecast, Italy, 2002-2013

Exhibit 6-39:  Obesity Drugs, Market Forecast, Italy, 2002-2013

Exhibit 6-40:  Obesity Drugs, Market Forecast, Spain, 2002-2013

Exhibit 6-41:  Obesity Drugs, Market Forecast, Spain, 2002-2013

Exhibit 6-42:  Obesity Drugs, Market Forecast, Scandinavia, 2002-2013

Exhibit 6-43:  Obesity Drugs, Market Forecast, Scandinavia, 2002-2013

Exhibit 6-44:  Obesity Drugs, Market Forecast, Japan, 2002-2013

Exhibit 6-45:  Obesity Drugs, Market Forecast, Japan, 2002-2013

Exhibit 6-46:  Obesity Drugs, Market Forecast, ROW, 2002-2013

Exhibit 6-47:  Obesity Drugs, Market Forecast, ROW, 2002-2013

Exhibit 7-1:  Alliance Opportunities

Exhibit 8-1:  Abbott Laboratories 2003 Sales by Division

Exhibit 8-2:  Johnson & Johnson and Subsidiaries, Division of Sales by Segment, 2003

Exhibit 8-3:  Inamed Corporation Sales, 2003

Exhibit 8-4:  Johnson & Johnson Worldwide Sales, 2003

Exhibit 8-5:  Johnson & Johnson Sales by Geographic Region, 2003

Exhibit 8-6:  Pfizer Divisions by Revenues, Fourth Quarter 2003

Exhibit 8-7:  Pfizer Drug Division Revenues as Percent of Total Human Pharmaceutical Revenues, Fourth Quarter 2003

Exhibit 8-8:  Roche Sales by Region, 2003

Exhibit 8-9:  Sanofi-Aventis 2003 Consolidated Sales

Exhibit 8-10:  Synovis Life Technologies Sales by Product Group, 2003

 


 

See the December 2010 Report #S835: Worldwide Obesity 2011-2019
Click HERE for more details.

 

(This report has been superseded by report #S835.) 
Products, Technologies and Markets Worldwide in the Clinical Management of Obesity

Report #S800, October 2004

Price

   

    $2,450 for print or PDF; $2,650 for both. (Add $1,500 for site license) [what's this?]

 

Order report online or via downloadable order form.

 

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

 

 Contact: Patrick Driscoll, (949) 859-3401.

Copyright © 2001-2004, MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

Or call
+1.949.891.1753

+1.949.859.3401
+1.949.837.4558 fax
1.866.820.1357 toll-free (US)

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports

 

White Paper
High Growth
Medical Technologies

October 2009

 

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us